---
title: US Oncology Genomics Tracker Sample
image: https://data.decibio.com/hubfs/Facebook%20Cover.jpg
---

# Sample Report

#### U.S. Oncology Genomics Tracker - Wave 5, Q2 2026

The focus of the U.S. Oncology Genomics Tracker is to characterize the current clinical use of genomic testing across clinical applications (e.g., genomic profiling, MRD / recurrence monitoring, treatment response monitoring) and track how use changes over time. Respondents were asked about use of genomic testing within routine clinical practice within the past 3 months.

The survey was distributed randomly to U.S. oncologists. Respondents were selected to complete the survey if they were an actively-practicing board-certified medical oncologist or hematologist-oncologist, U.S.-based and had seen at least 40 patients over the past 3 months. Respondents were not screened out of the survey if they were not currently using, or had not previously used, genomics for biomarker testing.

See more details below.

 

 

##### Complete this form to receive a copy of the sample report.

#### Survey Scope:

![Screenshot 2026-07-27 at 12.16.12 PM](https://data.decibio.com/hs-fs/hubfs/Screenshot%202026-07-27%20at%2012.16.12%20PM.png?width=1200&height=676&name=Screenshot%202026-07-27%20at%2012.16.12%20PM.png "Screenshot 2026-07-27 at 12.16.12 PM")

Respondent demographics from Wave 5 (Q2 2026) of the Oncology Genomics Tracker.

###### Survey Scope & Design:

- Structured as a recall-based survey
- For most questions, respondents were directed to answer in the context of patients treated and/or experiences within the past 3 months
- Respondents were directed to answer in the context of patients treated in routine clinical care and not in the context of clinical trials
- For MRD and monitoring, respondents were directed to answer in the context of solid-tumor testing
- Logic was used to display certain questions to respondents based on prior responses (e.g., familiarity, testing rates, etc.) – thus, not all respondents answered all questions (i.e.,respondents were not shown questions that were irrelevant to them based on their practices)
- The median duration of completion was 24 minutes

###### Survey Limitations / Considerations:

- **Survey format:** This is a recall-based survey, which relies on oncologists’ ability to recall specific information, which is imperfect
- **Survey N:** Given the number of medical oncologists / oncologist-hematologists in theU.S. (13,400), the 100 survey responses captured here represent a margin of error of 9-10% at a 95% confidence interval
- **Stakeholder type:** Oncologists are the primary stakeholder for deciding to order tests, but mayor may not be involved in actually executing the order (a nurse and / or pathologist can often play that role), thus the oncologist may not be entirely familiar with the details of the tests ordered (e.g., which types of tests from which labs)
- **Definitions: **Oncologist’s may have definitions that differ from those used / described in this survey and may have answered questions according to their personal definitions (e.g., some respondents included lymphomas in their definition of solid tumors, while others did not)
- **Selection bias:** Oncologists that actively and regularly order biomarker testing are more likely to take a survey related to oncology biomarker testing, potentially overrepresenting adoption and utilization figures, especially for emerging methods**‍**
- **Adherence to directions:** Oncologists were directed to answer the questions within a specific context(e.g., solid-tumor patients treated within routine care (i.e., not trials) within the past 3 months) – it is possible that oncologists deviated from these guardrails when responding to questions
- **Respondent mix:** The mix of respondents by setting for this survey (52% community-based, 48%AMC-based) is not mapped to the overall distribution of oncology care in theU.S. (which is closer to ~85% community-based, 15% AMC-based)
- **Volume vs. market share:** Any share figures here correspond to volume share and are not necessarily reflective of market share
- **Early access users:** Some clinicians / institutions participate in early-access programs which give them access to tests prior to public / commercial launch of an assay, which could be captured here